Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 4;10(5):721. doi: 10.3390/vaccines10050721

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Determination of CD4⁺ T cells activation ex vivo after immunization. The determination of three different activation markers, CD69, CD71, and CD25, was performed ex vivo in mice immunized with each of the recombinant BCG vaccine candidates. For rBCG-N-SARS-CoV-2, the activation of CD69 (A), CD71 (B), and CD25 (C) were evaluated in CD4⁺ T cells. For rBCG-N-ANDV, the activation of CD69 (D), CD71 (E), and CD25 (F) were evaluated in CD4⁺ T cells. Data are representative of 3 independent experiments. Each experiment considered a total of three mice per group. Statistical differences were assessed by two-way ANOVA with a post hoc Tukey test. *: p < 0.05; **: p < 0.01; ***: p < 0.001.